Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium

10/17/22 6:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NUVL alert in real time by email

CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that management will host a live webcast and conference call in conjunction with its data presentations at the 34th EORTC-NCI-AACR (ENA) Symposium in Barcelona, Spain on Friday, October 28, 2022 at 8:30 a.m. EDT.

The event will be accessible through the "Events" section of the Investors page of www.nuvalent.com or by dialing (866) 652-5200 (domestic) or (412) 317-6060 (international) and referring to conference ID 10171503. A replay and accompanying slides will be archived on the Nuvalent website for 30 days.

About Nuvalent

Nuvalent, Inc. (NASDAQ:NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), a program in HER2 Exon 20 insertion-positive cancers, along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-host-conference-call-to-discuss-preliminary-phase-1-data-from-arros-1-clinical-trial-of-nvl-520-and-additional-preclinical-updates-in-conjunction-with-34th-eortc-nci-aacr-symposium-301650281.html

SOURCE Nuvalent, Inc.

Get the next $NUVL alert in real time by email

Recent Analyst Ratings for

$NUVL

Date	Price Target	Rating	Analyst
10/24/2024	$100.00	Neutral	UBS
8/29/2024	$100.00	Overweight	Barclays
4/17/2024	$97.00	Buy	Jefferies
4/1/2024	$69.00 → $110.00	Market Perform → Outperform	Leerink Partners
2/28/2024	$99.00	Buy	Guggenheim
2/23/2024	$105.00	Outperform	Robert W. Baird
9/27/2023	$65.00	Buy	Stifel
8/8/2023	$42.00	Market Perform	SVB Securities

More analyst ratings

Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium

Chat with this insight

Recent Analyst Ratings for $NUVL

$NUVL SEC Filings

SEC Form 10-Q filed by Nuvalent Inc.

SEC Form 144 filed by Nuvalent Inc.

SEC Form 144 filed by Nuvalent Inc.

$NUVL Financials

Live finance-specific insights

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

$NUVL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

SEC Form SC 13G/A filed by Nuvalent Inc. (Amendment)

$NUVL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$NUVL Market Insights

Live Market Insights

UBS initiated coverage on Nuvalent with a new price target

Barclays initiated coverage on Nuvalent with a new price target

Jefferies initiated coverage on Nuvalent with a new price target

Nuvalent Begins Phase 1 Trial for New HER2-Selective Lung Cancer Treatment

Nuvalent To Present Updated Data From ARROS-1 Phase 1/2 Clinical Trial Of zidesamtinib And ALKOVE-1 Phase 1/2 Clinical Trial Of NVL-655 at ESMO Congress 2024

Stifel Maintains Buy on Nuvalent, Raises Price Target to $115

$NUVL Leadership Updates

Live Leadership Updates

Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors

Nuvalent Appoints Anna Protopapas as Chair of Board of Directors

Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

$NUVL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President and CEO Porter James Richard sold $2,374,479 worth of shares (27,000 units at $87.94) and exercised 27,000 shares at a strike of $27.85 (SEC Form 4)

Chief Development Officer Noci Darlene exercised 5,000 shares at a strike of $14.40 and sold $442,980 worth of shares (5,000 units at $88.60) (SEC Form 4)

Chief Financial Officer Balcom Alexandra sold $891,879 worth of shares (10,000 units at $89.19) and exercised 10,000 shares at a strike of $27.85 (SEC Form 4)

$NUVL Press Releases

Fastest customizable press release news feed in the world

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

Recent Analyst Ratings for
$NUVL

$NUVL
SEC Filings

$NUVL
Financials

$NUVL
Large Ownership Changes

$NUVL
Analyst Ratings

$NUVL
Market Insights

$NUVL
Leadership Updates

$NUVL
Insider Trading

$NUVL
Press Releases